← All stocks

NEKTAR THERAPEUTICS

NKTR Net selling
CIK 0000906709 #1869 in the set updated 18 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$2.43M
$2.09M on a plan · $0.00 straight out of an exercise
Sold at will
$346.41K
9 of 16 sales
Net
−$2.43M
−$346.41K against sales at will

By person

3 insiders · 16 transactions
3.5×

Howard W. Robin holds only 3.5 times base salary in stock. $3.93M of shares against $1.11M in salary for 2025.

Salary from the company's own proxy. The shares are what Howard W. Robin last reported holding, valued at $71.98, the price Common Stock was last bought or sold at on the open market here, on 18 Aug 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
ROBIN HOWARD W
President & CEO
$1.42M (8) scheduled
−$1.42M
54,627
$3.93M
Zalevsky Jonathan
Chief R&D Officer
$974.18K (7) scheduled
−$974.18K
9,570
$688.85K
Wilson Mark Andrew
Chief Legal Officer
$34.20K (1)
−$34.20K
21,585
$1.55M

No percentages here. This company's share count has moved by a factor of 9.8 over the window, from 19,018,573 to 186,103,588 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
Zalevsky Jonathan
30 Jun 2026
Chief R&D Officer
Sold on a plan
5,681
$70.00
$397.67K
ROBIN HOWARD W
17 Jun 2026
President & CEO
Sold on a plan
4,500
$61.65
$277.43K
ROBIN HOWARD W
17 Jun 2026
President & CEO
Sold on a plan
5,500
$60.81
$334.46K
ROBIN HOWARD W
16 Jun 2026
President & CEO
Sold on a plan
4,697
$60.71
$285.15K
ROBIN HOWARD W
16 Jun 2026
President & CEO
Sold on a plan
5,303
$59.97
$318.02K
Zalevsky Jonathan
15 Jun 2026
Chief R&D Officer
Sold on a plan
5,538
$60.71
$336.21K
Zalevsky Jonathan
20 Jan 2026
Chief R&D Officer
Sold on a plan
3,867
$35.67
$137.94K

What was left out

Form 4 filings counted 22
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 7
Sales straight out of an exercise 0
Sales at will 9
Transactions with no price 0
Shares from compensation/vesting 39,596
History held since 2 Sep 2016